Results 21 to 30 of about 22,313 (170)

Zidovudine plus Fosfomycin: synergistic effect against clinical isolates of multidrug-resistant Enterobacterales. In vitro and in vivo evidence. [PDF]

, 2021
In vitro synergistic activity between zidovudine (AZT) and fosfomycin against clinical isolates of MDR Enterobacteriaceae Background: Multidrug-resistant (MDR) Enterobacteriaceae are a priority health issue with few therapeutic options.
R. Luzzati, C. Lagatolla, F. Gigliucci, F. Fontana, R. M. Antonello, L. Furlanis, A. Knezevich, M. Busetti, F. Luzzaro, R. Tozzoli, R. La Ragione, L. Principe, V. Viaggi, J. Betts, S. Di Bella, S. Morabito, R. Bressan   +16 more
core  

The fosfomycin resistance gene fosB3 is located on a transferable, extrachromosomal circular intermediate in clinical Enterococcus faecium isolates. [PDF]

PLoS ONE, 2013
Some VanM-type vancomycin-resistant Enterococcus faecium isolates from China are also resistant to fosfomycin. To investigate the mechanism of fosfomycin resistance in these clinical isolates, antimicrobial susceptibility testing, filter-mating, Illumina/
Xiaogang Xu, Chunhui Chen, Dongfang Lin, Qinglan Guo, Fupin Hu, Demei Zhu, Guanghui Li, Minggui Wang   +7 more
doaj   +1 more source

Synergistic Effect of Cefazolin Plus Fosfomycin Against Staphylococcus aureus in vitro and in vivo in an Experimental Galleria mellonella Model

Frontiers in Pharmacology, 2021
Objectives: This study investigated the synergistic in vitro and in vivo activity of cefazolin plus fosfomycin against methicillin-susceptible and methicillin-resistant S.
Manuel Kussmann, Markus Obermueller, Matthias Karer, Matthias Karer, Richard Kriz, Rui-Yang Chen, Lena Hohl, Lisa Schneider, Heinz Burgmann, Ludwig Traby, Matthias G. Vossen   +10 more
doaj   +1 more source

The revival of fosfomycin [PDF]

, 2011
SummaryFosfomycin, originally named phosphonomycin, was discovered in Spain in 1969. There are three forms of fosfomycin: fosfomycin tromethamine (a soluble salt) and fosfomycin calcium for oral use, and fosfomycin disodium for intravenous use ...
Michalopoulos, Argyris S., Argyris S. Michalopoulos, Livaditis, Ioannis G., Gougoutas, Vassilios, Vassilios Gougoutas, Ioannis G. Livaditis   +5 more
core   +1 more source

Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant Acinetobacter baumannii Isolates in a Hollow-Fibre Infection Model

, 2022
Static concentration in vitro studies have demonstrated that fosfomycin- or sulbactam-based combinations may be efficacious against carbapenem-resistant Acinetobacter baumannii (CRAB).
Mohd Sazlly Lim, Sazlyna, Roberts, Jason A, Sazlyna Mohd Sazlly Lim, Lim, Sazlyna Mohd Sazlly, Heffernan, Aaron, Sime, Fekade Bruck, Saiyuri Naicker, Steven Wallis, Aaron Heffernan, Naicker, Saiyuri, Jason A. Roberts, Wallis, Steven, Fekade Bruck Sime, Roberts, Jason A.   +13 more
core   +1 more source

Susceptibility Profile of Nitrofurantoin and Fosfomycin among Carbapenem-resistant Enterobacteriaceae Isolates in UTI from a Tertiary Care Hospital [PDF]

, 2023
UTI is one of the most common infections requiring antibiotic treatment and hospitalization. The rising trend in multidrug resistance to commonly used antibiotics has reduced the therapeutic options for treating these infections.
K.V. Leela, Januki Kalai, D. Maheswary, Anusha Gopinathan   +3 more
core   +1 more source

Prevalence of fosfomycin resistance and gene mutations in clinical isolates of methicillin-resistant Staphylococcus aureus

Antimicrobial Resistance and Infection Control, 2020
Background Fosfomycin exhibits excellent in vitro activity against multidrug-resistant pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
Yi-Chien Lee, Pao-Yu Chen, Jann-Tay Wang, Shan-Chwen Chang   +3 more
doaj   +1 more source

Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii: A Prospective, Observational Study

Infectious Diseases and Therapy, 2020
Introduction Severe pneumonia caused by multidrug-resistant Acinetobacter baumannii (MDR-AB) remains a difficult-to-treat infection. Considering the poor lung penetration of most antibiotics, the choice of the better antibiotic regimen is debated ...
Alessandro Russo, Matteo Bassetti, Valeria Bellelli, Luigi Bianchi, Federica Marincola Cattaneo, Stefania Mazzocchetti, Elena Paciacconi, Fabrizio Cottini, Arcangelo Schiattarella, Giuseppe Tufaro, Francesco Sabetta, Alessandro D’Avino   +11 more
doaj   +1 more source

Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections. [PDF]

PLoS ONE, 2010
BACKGROUND: Fosfomycin is a cell wall inhibitor used efficiently to treat uncomplicated urinary tract and gastrointestinal infections. A very convenient feature of fosfomycin, among others, is that although the expected frequency of resistant mutants is ...
Alexandro Rodríguez-Rojas, María D Maciá, Alejandro Couce, Cristina Gómez, Alfredo Castañeda-García, Antonio Oliver, Jesús Blázquez   +6 more
doaj   +1 more source

Pharmacodynamics of Linezolid Plus Fosfomycin Against Vancomycin–Resistant Enterococcus faecium in a Hollow Fiber Infection Model

Frontiers in Microbiology, 2021
The optimal therapy for severe infections caused by vancomycin-resistant Enterococcus faecium (VREfm) remains unclear, but the combination of linezolid and fosfomycin may be a good choice.
Shuaishuai Wang, Shuaishuai Wang, Huiping Liu, Huiping Liu, Jun Mao, Jun Mao, Yu Peng, Yu Peng, Yisong Yan, Yisong Yan, Yaowen Li, Yaowen Li, Na Zhang, Na Zhang, Lifang Jiang, Lifang Jiang, Yanyan Liu, Jiabin Li, Xiaohui Huang, Xiaohui Huang   +19 more
doaj   +1 more source